Category

Archives

Dehydrogenase

ALDH1A1 maintains the cancer stem-like cells properties of esophageal squamous cell carcinoma by activating the AKT signal pathway and interacting with β-catenin

0 views | Mar 07 2022

Wei Wang et al. found that ALDH1A1 interacted with β-catenin, co-localization in KYS-510 cells. [Read the Full Post]

Discovery of linear unnatural peptides as potent mutant isocitrate dehydrogenase 1 inhibitors by Ugi reaction

114 views | Jan 23 2022

Xuechen Zhou et al. found that IDH1could decrease the cellular concentration of 2-HG, and suppress the proliferation of HT1080 and IDH1 mutant-U-87 cells by selectively inhibiting the activity of mutant IDH1. [Read the Full Post]

Dual-Knockout of Mutant Isocitrate Dehydrogenase 1 and 2 Subtypes Towards Glioma Therapy: Structural Mechanistic Insights on the Role of Vorasidenib

88 views | Jan 17 2022

Preantha Poonan et al. provided thorough structural and dynamic insights associated with the dual inhibitory activity of AG-881 towards glioma therapy. [Read the Full Post]

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial

144 views | Jan 17 2022

Ingo K Mellinghoff et al. found that vorasidenib was well tolerated and showed preliminary antitumor activity in patients with recurrent or progressive nonenhancing mIDH LGG. [Read the Full Post]

ALDH1A1 maintains the cancer stem-like cells properties of esophageal squamous cell carcinoma by activating the AKT signal pathway and interacting with β-catenin

223 views | Mar 18 2021

Wei Wang et al. found that ALDH1A1 expression maintained the CSC properties of ESCC cells. [Read the Full Post]

Population pharmacokinetic and exposure-response analyses of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies

223 views | Jan 30 2021

Xuemin Jiang et al. provided a framework to describe the relationship among ivosidenib dose, exposure, and clinical end points. [Read the Full Post]

MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma

261 views | Jan 25 2021

Abigail R Molloy et al. identified potential 1H- and 13C-MRS-detectable biomarkers of response to IDH1mut inhibition in gliomas. [Read the Full Post]

Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma

289 views | Jan 25 2021

Zenon Konteatis et al. described the discovery of vorasidenib (AG-881), a potent, oral, brain-penetrant dual inhibitor of both mIDH1 and mIDH2. [Read the Full Post]

Targeting the epigenome: Screening bioactive compounds that regulate histone deacetylase activity

0 views | Jan 30 2019

Godoy LD et al. provided the first step in identifying multiple bioactive compound HDAC inhibitors. [Read the Full Post]

Cell-based assay system for high-throughput screening of anti-photo-aging agents in fibroblast transfectants

0 views | Dec 21 2018

Lee S et al. revealed that CCN1-GFs treated with sclareol showed decreased levels of UVB-induced CCN1 expression. [Read the Full Post]